Technology | May 05, 2015

Biotronik Brings Closed Loop Simulation Sensor to Cardiac Resynchronization Defibrillators

Technology better mimics human nervous system to adjust heart whether user is stationary or in motion

Biotronik, CLS, Itrevia, CRT-D, heart failure

May 5, 2015 — Biotronik announced that a unique physiologic sensor is now available in the latest family of cardiac resynchronization therapy defibrillator (CRT-D) devices. Closed Loop Stimulation (CLS) is the only cardiac sensor capable of appropriately adapting heart rate in response to physiologic demands independent of body movements or respiratory rate.

Chronotropic incompetence – the inability of the heart to increase its rate to keep up with increased activity or demand — is common in many heart failure patients. When programmed in a Biotronik device, CLS provides appropriate rate response, similar to patients with healthy sinus nodes.

Most other CRT-D devices use accelerometers, which are mechanisms that sense physical activity and require patients to be in motion before increasing their heart rate. Yet, patients need appropriate rate response regardless of whether they are actively moving or completely stationary. CLS more closely mimics the human nervous system, responding to patients’ metabolic changes. It can sense and respond to acute mental stress, adjusting the heart rate without relying on motion. CLS, available in Biotronik pacemakers since 2003, has been proven to be more responsive in activities of daily living than accelerometers.

“I've treated many patients with Biotronik’s pacemakers equipped with CLS and have had excellent results,” said Chad E. Bonhomme, M.D., cardiac electrophysiologist with Community Health Network in Indianapolis, Indiana. “CLS in ICDs offers a new and exciting option to more closely mimic normal physiology.

"In addition to rate adaptation, I look forward to seeing the potential benefits of increased exercise tolerance, improved heart variability and diminished orthostatic symptoms," continued Bonhomme.

The latest Biotronik Itrevia ICD and CRT-D series includes other advanced atrial therapies: morphology discrimination, Vp suppression, atrial capture control, improved ATP optimization and left ventricle (LV) pacing vectors. Combined, they create more therapeutic options to deliver effective therapy while reducing painful shocks. All devices include Biotronik Home Monitoring, a remote monitoring system with automatic daily transmission, which has been shown to reduce all-cause mortality by over 50 percent.

For more information: www.biotronik.com

Related Content

Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
Israeli Hospital Completes First Implant of CORolla Heart Failure Device
News | Heart Failure| September 05, 2017
Rambam Hospital in Haifa, Israel, recently became the first to use the CORolla device from Israeli start-up company...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
Overlay Init